Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 28;5(8):e344.
doi: 10.1038/bcj.2015.70.

Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study

B K Hamilton  1 , L Rybicki  2 , H Haddad  3 , D Abounader  1 , M Yurch  1 , N S Majhail  1 , R Hanna  4 , R Sobecks  1 , R Dean  1 , H Liu  1 , B Hill  1 , E Copelan  5 , B Bolwell  1 , M Kalaycio  1
Affiliations

Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study

B K Hamilton et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of non-relapse mortality between patients who received full-dose MTX and omission of day 11 MTX.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735. - PubMed
    1. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005;11:383–388. - PubMed
    1. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7:193–198. - PubMed
    1. Atkinson K, Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant. 1995;16:755–758. - PubMed
    1. Honda A, Kakihana K, Aoki J, Kobayashi T, Doki N, Sakamaki H, et al. Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT. Bone Marrow Transplant. 2013;48:307–309. - PubMed

MeSH terms